RxDoctor Payments Data

David Wilterdink, MD

Family Medicine · Danielson, CTNPI 1538144548

Payments from drug & device makers

$3,787in general payments, 2019–2025

Across 215 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$631
  • Novo Nordisk$617
  • GSK$414
  • Boehringer Ingelheim$404
  • Astellas Pharma US Inc$223
  • Scilex Pharmaceuticals Inc.$205
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,69197%
  • Education$963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,787 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$70,424
Medicare patients
248
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban333$100,276
JardianceEmpagliflozin106$31,015
OzempicSemaglutide13$14,724
Breo ElliptaFluticasone/Vilanterol41$14,553
LinzessLinaclotide23$13,340
RytaryCarbidopa/Levodopa25$11,772
CreonLipase/Protease/Amylase11$10,597
MyrbetriqMirabegron31$10,576
Aripiprazole15$10,193
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$9,886
EntrestoSacubitril/Valsartan24$9,424
Aimovig AutoinjectorErenumab-Aooe11$8,772
Memantine Hcl80$8,338
Dexlansoprazole DrDexlansoprazole23$8,104
Atorvastatin Calcium449$6,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$100,276333 claims
Boehringer IngelheimJardiance, Stiolto Respimat$404$37,216118 claims
GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta$414$29,98777 claims
AbbVieLinzess, Creon$631$23,93734 claims
Novo NordiskOzempic$617$14,72413 claims
Astellas Pharma US IncMyrbetriq$223$10,57631 claims
NovartisEntresto$113$9,42424 claims
Johnson & JohnsonXarelto$98$5,35320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Danielson

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →